Oral etoposide maintenance for extensive stage SCLC: a phase III study

Oral etoposide maintenance treatment for extensive stage small cell lung cancer respond to induction chemotherapy: a phase III study

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-13003585

Enrollment

Unknown

Registered

2013-08-15

Start date

2013-10-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

small cell lung cancer

Interventions

OEM:oral etoposide maintenance

Control:observation

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Pathologically proved small cell lung cancer; 2. Extensive stage at diagnosis; 3. Aged 18 and above; 4. Respond (CR+PR) to 4 cycles prior induction EP chemotherapy; 5. Performance status is of ECOG 0-2; 6. No contraindication to oral etoposide; 7. Expectation of life was over 12 weeks; 8. Voluntary participation and signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Not controlled brain metastasis; 2. Only unevaluable tumor is present; 3. Pregnancy or lactation; 4. Combined with any unstable systemic diseases; 5. Deglutation disorder; 6. Combined with disease of digestive tract that would influence the drug absorption; 7. Abnormal mental state; 8. Patients with poor compliance who are unsuitable for this study.

Design outcomes

Primary

Measure	Time frame
Progression free survival;Overall survival;	—

Secondary

Measure	Time frame
Toxicities;Quality of life;	—

Countries

China

Contacts

Public ContactDr. Jiang Zhu

Department of thoracic oncology, cancer center, West China Hospital

zhujiang1@medmail.com.cn+86 028-18980602256

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026